Taysha Gene Therapies (TSHA) Gains from Investment Securities (2022 - 2025)
Taysha Gene Therapies (TSHA) has disclosed Gains from Investment Securities for 4 consecutive years, with -$597000.0 as the latest value for Q4 2025.
- Quarterly Gains from Investment Securities fell 665.38% to -$597000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$66.3 million through Dec 2025, down 293.26% year-over-year, with the annual reading at $24.6 million for FY2025, 563.83% up from the prior year.
- Gains from Investment Securities hit -$597000.0 in Q4 2025 for Taysha Gene Therapies, down from $23.6 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $100.0 million in Q3 2023 to a low of -$66.0 million in Q4 2023.
- Historically, Gains from Investment Securities has averaged $3.5 million across 4 years, with a median of $1.9 million in 2022.
- Biggest YoY gain for Gains from Investment Securities was 1296.38% in 2025; the steepest drop was 665.38% in 2025.
- Year by year, Gains from Investment Securities stood at -$23.9 million in 2022, then tumbled by 175.49% to -$66.0 million in 2023, then surged by 99.88% to -$78000.0 in 2024, then plummeted by 665.38% to -$597000.0 in 2025.
- Business Quant data shows Gains from Investment Securities for TSHA at -$597000.0 in Q4 2025, $23.6 million in Q3 2025, and $3.5 million in Q2 2025.